Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Topotecan in Second-line Small-cell Lung Cancer
NCT02980809Phase 2Unknown
- Sponsor
- First Hospital Affiliated to China PLA General Hospital
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in small cell lung cancer (SCLC), sponsored by First Hospital Affiliated to China PLA General Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02980809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980809.